The change in the lipid profile between the DPP-4 inhibitor and dapagliflozin showed a significant difference in HDL-C (p = 0.001) and LDL-C (p = 0.046) after analysis from ANCOVA after adjustment of age, sex, diabetes duration, BMI, and change of HbA1c, after DPP-4 inhibitor or SGLT2 inhibitor therapy. This evidence concerns the gene SLC5A2 and diabetes mellitus.